ProFuse Technology Information

ProFuse is a biotechnology company dedicated to the discovery and development of first-in-class muscle therapeutics and dietary supplements, providing highly translatable solutions for sarcopenia and GLP-1-induced muscle loss. Leveraging a proprietary high-throughput human skeletal muscle platform, the company identifies novel muscle-targeted compounds with high clinical relevance for muscle atrophy and metabolic diseases. ProFuse is advancing its internal programs while engaging in strategic partnerships with pharma and biotech companies. Key recent milestones: 1) Screening momentum: launched screening campaign with a leading global CRO, targeting a throughput of over 10,000 small molecules per week in a muscle atrophy model. 2) Pipeline development: identifying novel therapeutics and dietary supplements across multiple indications, including muscle atrophy associated with metabolic interventions (e.g., GLP-1–based therapies) and sarcopenia. 3) Funding: successfully closed equity financing to drive the advancement of selected hits into lead optimization. Building on scientific breakthroughs from the Weizmann Institute of Science, ProFuse has further advanced and refined its proprietary platform through years of dedicated research in muscle biology. While the field has long relied on models with limited predictive value, ProFuse enables predictive, high-throughput screening in physiologically relevant human muscle systems. The platform integrates advanced functional readouts and disease-relevant modeling across 2D and 3D assays, supporting the efficient discovery of therapeutics and dietary supplements with strong translational relevance.